Provided by Tiger Trade Technology Pte. Ltd.

4D Molecular Therapeutics

8.48
-0.1600-1.85%
Post-market: 8.490.0100+0.12%19:39 EST
Volume:516.91K
Turnover:4.38M
Market Cap:432.55M
PE:-2.26
High:8.68
Open:8.40
Low:8.19
Close:8.64
52wk High:12.34
52wk Low:2.24
Shares:51.01M
Float Shares:36.78M
Volume Ratio:0.49
T/O Rate:1.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7446
EPS(LYR):-2.9821
ROE:-45.38%
ROA:-27.64%
PB:1.17
PE(LYR):-2.84

Loading ...

4D Molecular Therapeutics Chief Legal Officer Scott Bizily Reports Disposal of Common Shares

Reuters
·
Oct 21, 2025

4D Molecular Therapeutics Grants 25,450 RSUs to New Employees Under 2025 Inducement Plan

Reuters
·
Oct 18, 2025

4D Molecular Therapeutics Chief Legal Officer Scott Bizily Reports Disposal of Common Shares

Reuters
·
Oct 15, 2025

4D Molecular Therapeutics Inc. to Participate in Chardan's 9th Annual Genetic Medicines Conference

Reuters
·
Oct 14, 2025

4D Molecular Therapeutics Receiving $11 Million in Funding for Cystic Fibrosis Study

MT Newswires Live
·
Oct 13, 2025

BRIEF-4Dmt Advances 4D-710 To Phase 2 With Additional Funding

Reuters
·
Oct 13, 2025

4Dmt Advances 4D-710 to Phase 2 With Additional Funding and Support From the Cystic Fibrosis Foundation

THOMSON REUTERS
·
Oct 13, 2025

4D Molecular Therapeutics Inc - CF Foundation to Invest up to $11 Mln in 4Dmt Equity in 2 Tranches

THOMSON REUTERS
·
Oct 13, 2025

4D Molecular Therapeutics Inc. Files Initial Beneficial Ownership Statement for Ashoo Gupta, VP Finance and Controller

Reuters
·
Oct 11, 2025

BRIEF-4D Molecular Therapeutics Says On Sept 30, Appointed Ashoo Gupta As Principal Financial Officer - SEC Filing

Reuters
·
Oct 03, 2025

4D Molecular Therapeutics Inc - on Sept 30, Appointed Ashoo Gupta as Principal Financial Officer - SEC Filing

THOMSON REUTERS
·
Oct 03, 2025

4D Molecular Therapeutics Amends and Restates Company Bylaws

Reuters
·
Oct 03, 2025

4D Molecular Therapeutics Inc. Chief Legal Officer Scott Bizily Reports Disposal of Common Shares

Reuters
·
Sep 27, 2025

H.C. Wainwright Reaffirms Their Buy Rating on 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
Sep 19, 2025

4D Molecular Therapeutics Grants 40,900 Restricted Stock Units to New Employees Under 2025 Employment Inducement Plan

Reuters
·
Sep 13, 2025

4D Molecular Therapeutics Announces Key Leadership Changes: Julie Clark Appointed Chief Medical Officer as Company Prepares for Late-Stage Clinical Trials

Reuters
·
Sep 02, 2025

4Dmt Announces Leadership Expansion With Proven Late-Stage Executives to Drive 4D-150 Execution and Bla Readiness

THOMSON REUTERS
·
Sep 02, 2025